Literature DB >> 20538056

Carnitine palmitoyltransferase 2: New insights on the substrate specificity and implications for acylcarnitine profiling.

Sara Violante1, Lodewijk Ijlst, Henk van Lenthe, Isabel Tavares de Almeida, Ronald J Wanders, Fátima V Ventura.   

Abstract

Over the last years acylcarnitines have emerged as important biomarkers for the diagnosis of mitochondrial fatty acid beta-oxidation (mFAO) and branched-chain amino acid oxidation disorders assuming they reflect the potentially toxic acyl-CoA species, accumulating intramitochondrially upstream of the enzyme block. However, the origin of these intermediates still remains poorly understood. A possibility exists that carnitine palmitoyltransferase 2 (CPT2), member of the carnitine shuttle, is involved in the intramitochondrial synthesis of acylcarnitines from accumulated acyl-CoA metabolites. To address this issue, the substrate specificity profile of CPT2 was herein investigated. Saccharomyces cerevisiae homogenates expressing human CPT2 were incubated with saturated and unsaturated C2-C26 acyl-CoAs and branched-chain amino acid oxidation intermediates. The produced acylcarnitines were quantified by ESI-MS/MS. We show that CPT2 is active with medium (C8-C12) and long-chain (C14-C18) acyl-CoA esters, whereas virtually no activity was found with short- and very long-chain acyl-CoAs or with branched-chain amino acid oxidation intermediates. Trans-2-enoyl-CoA intermediates were also found to be poor substrates for CPT2. Inhibition studies performed revealed that trans-2-C16:1-CoA may act as a competitive inhibitor of CPT2 (K(i) of 18.8 microM). The results obtained clearly demonstrate that CPT2 is able to reverse its physiological mechanism for medium and long-chain acyl-CoAs contributing to the abnormal acylcarnitines profiles characteristic of most mFAO disorders. The finding that trans-2-enoyl-CoAs are poorly handled by CPT2 may explain the absence of trans-2-enoyl-carnitines in the profiles of mitochondrial trifunctional protein deficient patients, the only defect where they accumulate, and the discrepancy between the clinical features of this and other long-chain mFAO disorders such as very long-chain acyl-CoA dehydrogenase deficiency. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538056     DOI: 10.1016/j.bbadis.2010.06.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  16 in total

1.  Sodium butyrate epigenetically modulates high-fat diet-induced skeletal muscle mitochondrial adaptation, obesity and insulin resistance through nucleosome positioning.

Authors:  Tara M Henagan; Barbara Stefanska; Zhide Fang; Alexandra M Navard; Jianping Ye; Natalie R Lenard; Prasad P Devarshi
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

2.  Peroxisomal oxidation of erucic acid suppresses mitochondrial fatty acid oxidation by stimulating malonyl-CoA formation in the rat liver.

Authors:  Xiaocui Chen; Lin Shang; Senwen Deng; Ping Li; Kai Chen; Ting Gao; Xiao Zhang; Zhilan Chen; Jia Zeng
Journal:  J Biol Chem       Date:  2020-06-03       Impact factor: 5.157

Review 3.  Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.

Authors:  Stephanie E Reuter; Allan M Evans
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

4.  Acyl-CoA thioesterase-2 facilitates mitochondrial fatty acid oxidation in the liver.

Authors:  Cynthia Moffat; Lavesh Bhatia; Teresa Nguyen; Peter Lynch; Miao Wang; Dongning Wang; Olga R Ilkayeva; Xianlin Han; Matthew D Hirschey; Steven M Claypool; Erin L Seifert
Journal:  J Lipid Res       Date:  2014-08-11       Impact factor: 5.922

5.  Effect of hemodialysis session on the dynamics of carnitine ester profile changes in L-carnitine pretreated end-stage renal disease patients.

Authors:  Botond Csiky; Judit Bene; Istvan Wittmann; Endre Sulyok; Bela Melegh
Journal:  Int Urol Nephrol       Date:  2012-06-10       Impact factor: 2.370

Review 6.  Metabolic interactions between peroxisomes and mitochondria with a special focus on acylcarnitine metabolism.

Authors:  Sander M Houten; Ronald J A Wanders; Pablo Ranea-Robles
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-02-10       Impact factor: 5.187

7.  Altered body composition and energy expenditure but normal glucose tolerance among humans with a long-chain fatty acid oxidation disorder.

Authors:  Melanie B Gillingham; Cary O Harding; Dale A Schoeller; Dietrich Matern; Jonathan Q Purnell
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-09-24       Impact factor: 4.310

8.  Mechanical unloading promotes myocardial energy recovery in human heart failure.

Authors:  Anisha A Gupte; Dale J Hamilton; Andrea M Cordero-Reyes; Keith A Youker; Zheng Yin; Jerry D Estep; Robert D Stevens; Brett Wenner; Olga Ilkayeva; Matthias Loebe; Leif E Peterson; Christopher J Lyon; Stephen T C Wong; Christopher B Newgard; Guillermo Torre-Amione; Heinrich Taegtmeyer; Willa A Hsueh
Journal:  Circ Cardiovasc Genet       Date:  2014-05-13

9.  Muscle MRI in patients with long-chain fatty acid oxidation disorders.

Authors:  Eugene F Diekman; W Ludo van der Pol; Rutger A J Nievelstein; Sander M Houten; Frits A Wijburg; Gepke Visser
Journal:  J Inherit Metab Dis       Date:  2013-12-05       Impact factor: 4.982

10.  Fatty acid oxidation flux predicts the clinical severity of VLCAD deficiency.

Authors:  Eugene F Diekman; Sacha Ferdinandusse; Ludo van der Pol; Hans R Waterham; Jos P N Ruiter; Lodewijk Ijlst; Ronald J Wanders; Sander M Houten; Frits A Wijburg; A Christiaan Blank; Folkert W Asselbergs; Riekelt H Houtkooper; Gepke Visser
Journal:  Genet Med       Date:  2015-04-02       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.